12 Consumer Discretionary Stocks Moving In Wednesday’s Intraday Session

Gainers Connexa Sports Techs (NASDAQ:CNXA) shares rose 128.0% to $0.45 during Wednesday’s regular session. The market value of…

Gainers

  • Connexa Sports Techs (NASDAQ:CNXA) shares rose 128.0% to $0.45 during Wednesday’s regular session. The market value of their outstanding shares is at $1.5 million.
  • Envirotech Vehicles (NASDAQ:EVTV) stock moved upwards by 19.86% to $1.75. The company’s market cap stands at $26.4 million.
  • Jiuzi Hldgs (NASDAQ:JZXN) stock rose 14.14% to $0.72. The company’s market cap stands at $2.9 million.
  • 17 Education & Technology (NASDAQ:YQ) stock rose 10.16% to $2.39. The company’s market cap stands at $23.2 million.
  • Canoo (NASDAQ:GOEV) shares rose 9.2% to $0.2. The market value of their outstanding shares is at $188.9 million.
  • Naas Technology (NASDAQ:NAAS) stock rose 9.09% to $1.56. The market value of their outstanding shares is at $381.5 million.

Losers

  • Kaixin Auto Hldgs (NASDAQ:KXIN) stock fell 45.2% to $0.4 during Wednesday’s regular session. The market value of their outstanding shares is at $10.6 million.
  • Esports Entertainment (NASDAQ:GMBL) shares fell 25.46% to $2.46. The market value of their outstanding shares is at $2.6 million.
  • Selina Hospitality (NASDAQ:SLNA) stock declined by 17.91% to $0.41. The market value of their outstanding shares is at $44.8 million.
  • Boqii Holding (AMEX:BQ) shares declined by 15.86% to $0.31. The company’s market cap stands at $1.4 million.
  • Polished.com (AMEX:POL) shares declined by 11.24% to $4.9. The market value of their outstanding shares is at $10.3 million.
  • BowFlex (NYSE:BFX) shares decreased by 9.83% to $0.63. The company’s market cap stands at $22.9 million.
    See Also: www.benzinga.com/money/best-consumer-cyclical-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Why Ocugen Stock Is Climbing Today

Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen said the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 has  approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.

OCGN